The importance of biologically active vitamin D for mineralization by osteocytes after parathyroidectomy for renal hyperparathyroidism

Aiji Yajima M.D.,¹,² Ken Tsuchiya M.D.,³ David B. Burr Ph.D.,¹ Joseph M. Wallace Ph.D.,⁴ John D. Damrath Ph.D.,⁴ Masaaki Inaba M.D.,⁵ Yoshihiro Tominaga M.D.,⁶ Shigeru Satoh M.D.,⁷ Takashi Nakayama M.D.,⁸ Tatsuhiko Tanizawa M.D.,⁹ Hajime Ogawa M.D.,¹⁰ Mrs. Akemi Ito.,¹¹ Kosaku Nitta M.D.²

¹Department of Anatomy and Cell Biology, Indiana University, School of Medicine, Indianapolis, IN, USA, ²Department of Medicine, Kidney Center, Tokyo Women’s Medical University, Shinjuku-ku, Tokyo, Japan, ³Department of Blood Purification, Kidney Center, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Department of Biomedical Engineering, Indiana University, Purdue University, Indianapolis, IN, USA, ⁵Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka-City, Osaka, Japan, ⁶Department of Transplant Surgery, Nagoya Second Red Cross Hospital, Nagoya-City, Aichi, Japan, ⁷Center for Kidney Disease and Transplantation, Akita University Hospital, Akita-City, Akita, Japan, ⁸Department of Orthopedic Surgery, Towa Hospital, Adachi-ku, Tokyo, Japan, ⁹Department of Orthopedic Surgery, Tanizawa Clinic, Niigata-City, Niigata, Japan, ¹⁰Department of Medicine, Division of Nephrology, Ogawa Clinic, Shinagawa-ku, Tokyo, Japan, ¹¹Ito Bone Histomorphometry Institute, Niigata-City, Niigata, Japan

Corresponding author; Aiji Yajima M.D.,

Street address; VanNuys Medical Science Building, 635 Barnhill Dr., MS5035,
Indianapolis, IN, 46202, USA

Phone number: +1-317-681-9939

E-mail address: a-and-y@rj8.so-net.ne.jp, Clinical paper

Grant: none

AY, KT, DBB, JMW, JDD, MI, YT, SS, TN, TT, HO, AI and KN qualify for authorship.
Disclosures/Conflicts of Interest.

The authors state that they have no conflicts of interest.
ABSTRACT

Background

Hypomineralized matrix is a factor determining bone mineral density. Increased perilacunar hypomineralized bone area is caused by reduced mineralization by osteocytes. The importance of vitamin D in the mineralization by osteocytes was investigated in hemodialysis patients who underwent total parathyroidectomy (PTX) with immediate autotransplantation of diffuse hyperplastic parathyroid tissue. No previous reports on this subject exist.

Methods

The study was conducted in 19 patients with renal hyperparathyroidism treated with PTX. In 15 patients, the serum calcium levels were maintained by subsequent administration of alfacalcidol (2.0 μg/day), intravenous calcium gluconate, and oral calcium carbonate for four weeks after PTX (Group I). This was followed in a subset of four patients in Group I by a reduced dose of 0.5 μg/day until one year following PTX; this was defined as Group II. In the remaining four patients, who were not in Group I, the serum calcium levels were maintained without subsequent administration of alfacalcidol (Group III). Transiliac bone biopsy specimens were obtained in all groups before and 3 or 4 weeks after PTX to evaluate the change of hypomineralized bone area. In addition, patients from Group II underwent a third bone biopsy one year following PTX.

Results

A significant decrease of perilacunar hypomineralized bone area was observed 3 or 4 weeks after PTX in all Group I and II patients. The area was increased again in the Group II patients one year following PTX. In Group III patients, an increase of
hypomineralized bone area was observed four weeks after PTX.

**Conclusion**

The maintenance of a proper dose of vitamin D is necessary for mineralization by osteocytes, which is important to increase bone mineral density after PTX for renal hyperparathyroidism.

**Key words**

Mineralization, Osteocyte, Vitamin D
Introduction

Accumulated evidence suggests that the osteocyte is a crucial determinant of bone strength. The osteocyte network spreads extensively over the skeleton controlling osteocytic perilacunar/canalicular turnover and regulating some functions of osteoclasts and osteoblasts. Figure 1 was taken from a hemodialysis (HD) patient with renal hyperparathyroidism in this study, but it is not a result of this study. This figure was adopted to show the relationships between osteocytes and both osteoclasts and osteoblasts in HD patients with renal hyperparathyroidism (Figure 1). However, there have been few clinical papers about the role of the osteocyte in patients with chronic kidney disease (CKD) (Figure 1). It is likely that bone fragility in CKD patients suffering from renal hyperparathyroidism increases as a result of increased hypomineralized bone area caused by impaired mineralization by osteocytes, increased woven bone area, and the reduced cortical bone area caused by cortical thinning and increased cortical porosity. The long-term reduction of osteocyte number generally leads to increased fracture risk.

Parathyroidectomy is an important treatment option for hyperparathyroid bone disease caused by renal hyperparathyroidism because this procedure is completed in about one hour with little bleeding. However, whether mineralized bone area generally increases following parathyroidectomy has not been also clarified. It was reported that parathyroidectomy with or without subsequent Vit. D administration increases bone mineral and reduces fracture risk of dialysis patients, but the importance of subsequent administration of biologically active vitamin D after parathyroidectomy on mineralization on lacunar surfaces by osteocytes has not been well studied. Total parathyroidectomy (PTX) with immediate autotransplantation of 150 mg of diffuse
hyperplastic parathyroid tissue is really important in patients with severe renal hyperparathyroidism.\(^7,19\) Osteoblast surface (Ob.S/BS) increases 1 week after parathyroidectomy and low turnover osteomalacia with severe hypophosphatemia transiently develops 4 weeks after the surgery, thereafter, serum phosphorus level gradually increases. And bone mineral density (BMD) is significantly increased after parathyroidectomy as presented in the previous papers.\(^7,18,19\) Thus, mineralization by osteocytes is critical to increase BMD in CKD patients, and its importance has been demonstrated in both CKD patients and animal models without CKD.\(^1-3,4,7\)

We have demonstrated increased osteocyte death and mineralization at the osteocytic perilacunar/canalicular surface after PTX.\(^7\) And the degree of mineralization at the osteocytic perilacunar/canalicular surface is greater than that at the mineralization front by osteoblasts after PTX with subsequent administration of 2.0 μg/day of alfacalcidol (1α-hydroxyvitamin D\(_3\); Chugai Pharma Co. Ltd., Tokyo, Japan).\(^7\) The existence of the parathyroid hormone receptor\(^20\) and the effects of biologically activated Vit. D on the vitamin D receptor\(^21\) expressed by the osteocyte may affect these changes. Moreover, the number of osteocytes is markedly greater than that of osteoblasts\(^22\) and there is significantly more surface area for molecular exchange associated with osteocyte lacunae and canaliculi (1200 m\(^2\)) than that found in Haversian/Volkmann’s canals (3.2 m\(^2\)) or cancellous surfaces (9.0 m\(^2\)) in the male skeleton.\(^23\)

The importance of activated Vit. D for mineralization by osteocytes in CKD patients must be explored. In this study, the change of hypomineralized bone area was analyzed in HD patients with and without Vit. D supplementation after PTX to ascertain the importance of Vit. D in perilacunar/canalicular mineralization by osteocytes.
Materials and Methods

Study design

Six females and 13 males with an average age of 58.4 ± 8.8 (39-71) years who were under maintenance by HD were enrolled in this study. They had been on HD for an average of 14.1 ± 7.3 (1-25) years. Because the sensitivity of bone tissue to parathyroid hormone (PTH) is reduced in patients with diabetes mellitus, none of the patients in this clinical study suffered from diabetes mellitus. If the serum levels of intact PTH were > 1000 pg/mL or total alkaline phosphatase was > 360 U/L in the HD patients, the patients with renal hyperparathyroidism were treated with PTX. This was usually because the condition was refractory to conservative therapy with Vit. D sterols. We included all patients who received PTX between 1996 and 2010. No patients received cinacalcet hydrochloride (HCl) (Amgen Inc. Thousand Oaks, CA, USA, Kyowa Hakko Kirin, Tokyo, Japan) treatment before PTX (Table 1).

The 19 patients with renal hyperparathyroidism were divided into the three groups. - Group I, consisted of patients (n = 15) who received subsequent administration of 2.0 μg/day of alfacalcidol for 3-4 weeks after PTX. - Group II, consisted of a subset of 4 patients from Group I who received subsequent administration of 2.0 μg/day of alfacalcidol for 4 weeks after PTX, but a reduced dose of alfacalcidol (0.5 μg/day) from 4 weeks to one year following PTX. Group III, consisted of a separate group of patients (n = 4) did not receive alfacalcidol administration postoperatively due to Vit. D allergy or to avoid extraosseous ossification caused by high Vit. D levels after surgery. Serum PTH levels must be increased to avoid long-term low turnover bone disease to avoid increased microcracks and soft tissue ossification after PTX. Ca containing drugs, including intravenous Ca gluconate and oral Ca carbonate were administered to
all Group I and II patients to maintain the proper serum Ca levels, but the four patients of Group III received only Ca gluconate and Ca carbonate after PTX to avoid severe hypocalcemia. Serum Ca levels were measured once a couple of days after PTX. The dose of Ca administered was 57.5 ± 17.1 g (22.5-73.6 g) to the fifteen Group I patients and 37.0 ± 13.5 g (24.3-55.4 g) to Group III patients during the first 4 weeks after PTX. Transiliac bone biopsy specimens were obtained from the left iliac crest before PTX and from the right iliac crest 3 weeks (n = 3) or 4 weeks (n = 12) after PTX in Group I and before and 4 weeks after surgery in Group III (n = 4). In addition, the four patients from Group II (a subset of Group I) underwent a third bone biopsy from the left iliac crest 1 year after PTX. As a result, the four Group II patients received bone biopsies three times (pre-surgery, 3-4 weeks after PTX, and one year after PTX). The patients were included only after consent was obtained.

Parathyroidectomy

A total of 19 HD patients received PTX for renal hyperparathyroidism after failure or lack of Vit. D therapy, and four or five parathyroid glands were successfully removed under general anesthesia in the patients. After the surgery, 150 mg of diffuse hyperplastic parathyroid tissue was autotransplanted into the adipose tissue of the abdominal wall,\(^{7,19}\) to avoid complications caused by long-term low bone turnover.\(^{27-29}\) In these 19 patients, serum intact PTH levels were measured by an immunoradiometric assay (Allegro intact PTH, Nichols Institute Diagnostics, San Juan Capistrano, CA, USA) or an electrochemiluminescence immunoassay (Elecsys PTH, Roche Diagnostics, GmbH, Mannheim, Germany); intact PTH levels fell to 25 pg/mL or less one week after PTX. In one patient, three parathyroid glands were removed and
serum intact PTH fell from 1092 to 212 pg/mL one week later and further to 76 pg/mL 4 weeks after PTX. In this patient, 50 mg of diffuse hyperplastic parathyroid tissue had been autotransplanted. Nodular hyperplastic parathyroid tissue was not autotransplanted as it is highly possible for recurrence of hyperparathyroidism to occur after PTX.\(^{(30)}\) All patients resumed walking two days after PTX, because mechanical loading is important to maintain bone properties.\(^{(31-33)}\) These patients were treated with PTX with immediate autotransplantation between 1996 and 2010.

Serum bone metabolism parameters

The serum levels of intact PTH, tartrate-resistant acid phosphatase (TRACP; Means of colorimetry, using \(\rho\)-nitrophenyl phosphate as the substrate), deoxypyridinoline (DPD; High-performance liquid chromatography), carboxy-terminal propeptide of human type I procollagen (PICP; Radioimmunoassay kit (PICP ORION; Orion Diagnostica, Espoo, Finland)), and total alkaline phosphatase (total-ALP; Means of colorimetry, using \(\rho\)-nitrophenyl phosphate as the substrate) were measured before and 3.8 ± 0.4 (3 or 4) weeks after PTX in Groups I and II, and before and 4 weeks after PTX in Group III, although serum bone metabolism parameters are not sometimes reliable in HD patients.\(^{(34)}\) Serum intact PTH, calcium (Ca) and phosphorus (P) levels were measured and compared between 4 weeks and 1 year after PTX in Group II (Table 2). Blood samples were collected immediately before PTX and immediately before the iliac bone biopsies performed 4 weeks after PTX. Plasma 1.25(OH)\(_2\)D\(_3\) (Immuno Diagnostic Systems Ltd, Boldon, UK radioimmunoassay kit) levels were measured in Group III patients, but not in Groups I or II.
Bone histomorphometry

Tetracycline hydrochloride (Japan Lederle, Tokyo, Japan) was administered for 2 or 3 days with an inter-label period of 8 to 13 days. A 3-4 day washout period was allowed before the biopsy was taken in the patients. Static and dynamic histomorphometric parameters defined by Dempster et al. and Recker et al. were measured in the central portion of cancellous bone.\(^{(35,36)}\) In addition, the hypomineralized bone area normalized to total bone area (hypomineralized bone area; HM.B.Ar/B.Ar; \(\%\))\(^{(10,11)}\) was measured at the central portion of the cancellous bone by fluorescent light microscopy.

Osteoclast surface (Oc.S/BS), eroded surface (ES/BS), osteoblast surface (Ob.S/BS) and osteoid surface (OS/BS) were measured in cancellous bone and statistically compared before and after PTX in all groups, and also 4 weeks and 1 year after PTX in Group II. Bone formation rate normalized to bone surface (BFR/BS; \(\text{mm}^3/\text{mm}^2/\text{year}\)) was measured 3-4 weeks after PTX in Groups I and III. However, BFR/BS was not measured one year after PTX in Group II. Hypomineralized bone area was measured in cancellous bone to compare the values obtained before and 3-4 weeks after PTX in all groups, and 4 weeks and 1 year after PTX in Group II.

Raman spectroscopy

Embedded biopsies were sanded to create a flat surface and then polished with a 3 \(\mu\)m diamond suspension followed by a 50 nm alumina suspension. We did Raman measurements from the same sections as those used for histology, but were not able to specifically target hypomineralized areas for measurement. Bone near edges was likely more plasticized than tissue in more centrally located regions, so all measures were targeted toward bone away from edges. However, given the current laser setup on the
Raman scope, we were not able to visualize any labels. Bone samples from nine patients were chosen for the Raman spectroscopy because these were the only patients for whom we could get informed consent to perform another analysis. Also, several patients had died before we were able to ask their permission for this analysis. Raman spectroscopy was performed using an InVia Raman Spectrometer (Renishaw, Wotton-under-Edge, United Kingdom). A 785 nm laser was focused on the bone surface using a 50X objective to a spot size of ~1.3 μm. Eight sites within the trabecular regions were imaged ~1 mm apart. Spectra were acquired following a 12s exposure and were averaged across 12 accumulations. Baseline correction was accomplished using Renishaw WiRE software intelligent fitting. Gaussian peaks were fit to the PO₄³⁻-ν₁ peak, and CO₃²⁻-ν₁, peaks by second derivative spectroscopy in GRAMS/AI (Thermo Fisher Scientific, Waltham, MA). The extent of matrix mineralization was determined by the mineral/matrix ratio, calculated as the integrated area ratio of PO₄³⁻-ν₁/Amide I. Mineral maturity/crystallinity was calculated as the inverse of the full width at half height of the PO₄³⁻-ν₁ Gaussian peak. Type B carbonate substitution was calculated as the Gaussian peak area ratio of PO₄³⁻-ν₁/CO₃²⁻-ν₁. The 8 spectra acquired for each sample were averaged, yielding a single value for each Raman parameter to be used for analysis.⁴⁷

Informed consent was obtained from all patients after they were provided with a detailed explanation of both the risks and possible outcomes of bone biopsies and PTX. The procedure was conducted in accordance with the Declaration of Helsinki, and the study protocol was approved by the Institutional Review Board of Towa Hospital and its affiliated hospitals. The Institutional Review Board of Towa Hospital and its affiliated hospitals approved the study protocol.
Statistical Analysis

Statistical analyses were conducted using JMP 13 (SAS Institute Inc., North Carolina, USA). The parameters pertaining to serum bone metabolism, histomorphometric parameters of bone turnover and hypomineralized bone area, and parameters obtained by Raman spectroscopy were compared with each other using nonparametric tests (Mann Whitney tests) or unpaired Student’s t tests. The parameters obtained by Raman spectroscopy were also compared before and after PTX using the Mann-Whitney test. Power analysis was computed with JMP post hoc using calculated means, standard deviations and sample size for each group and variable, and presented in Tables 2-5.

Results

Serum bone metabolism parameters

Serum resorption parameters, including TRACP and DPD levels decreased and serum formation parameters, including PICP and total-ALP levels significantly increased after PTX in Group I (Table 2 (1)). Serum resorption parameters decreased and serum formation parameters increased in the four patients in Group III (Table 2 (3)), but neither of these differences was significant. Serum Ca levels remained unchanged, probably because they were maintained by intravenous Ca gluconate and oral Ca carbonate administration after PTX. Serum P levels significantly decreased after PTX in both Groups I and III (Tables 2 (1) and (3)). Plasma 1.25(OH)$_2$D$_3$ levels were extremely low in Group III patients (5.3 ± 2.2 (2.8-7.9) pg/mL); the normal range of plasma 1.25(OH)$_2$D$_3$ level is from 20 to 60 pg/mL.
Histomorphometry of bone turnover

Resorption parameters decreased after PTX in Group I (Table 3 (1)). Although Ob.S/BS was not significantly different before and after PTX (p = 0.083), OS/BS increased in Group I, possibly because of hypophosphatemia and a failure to mineralize newly deposited matrix (Table 3 (1)). In Group II, Oc.S/BS increased from 0 to 0.1 % one year after PTX (Table 3 (2)), probably because serum intact PTH increased by three-fold one year after surgery (Table 2 (2)). Bone resorption parameters (Oc.S/BS and ES/BS) decreased in all four patients after PTX in Group III, although the changes were not statistically significant (Table 3 (3)), probably because of the small sample size. BFR/BS was 0.020 ± 0.015 (0.003-0.032) mm³/mm²/year in Group I (Table 3 (1)) and was 0.026 ± 0.033 (0-0.070) mm³/mm²/year in Group III (Table 3 (3)) 4 weeks after PTX, but there was no statistical difference between these two groups even though Ob.S/BS was significantly greater in Group III than in Group I after PTX (Table 4).

Histomorphometry of hypomineralized bone area

HM.B.Ar/B.Ar significantly decreased from 17.3 ± 12.8 to 2.6 ± 3.2 % (p 0.001) after PTX in the Group I patients (Table 3 (1), Figures 2, 3a and 3b). These parameters were also compared between 4 weeks and 1 year after PTX in the four patients who underwent a third biopsy (Group II) after the dose of alfacalcidol was reduced from 2.0 to 0.5 μg/day at 4 weeks. HM.B.Ar/B.Ar increased in all four patients (2.5 ± 1.8 vs. 14.4 ± 5.0 %, p = 0.125) one year after PTX (Table 3 (2), Figure 2). In Group III, who did not receive alfacalcidol after PTX, HM.B.Ar/B.Ar increased in all four patients (6.0 ± 4.0 vs. 14.3 ± 3.5 %, p = 0.125) (Table 3 (3), Figures 4a, 4b and 4c). HM.B.Ar/B.Ar was significantly greater in Group I than in Group III after PTX (Table 4).
Raman spectroscopy for mineral matrix ratio, mineral maturity and crystallinity

The mineral-matrix ratio, shown as $\text{PO}_4^{3-}/\text{ν1/Amide I}$, did not change following PTX surgery in Group I ($n = 6$; $2.317 \pm 0.346$ before PTX and $2.346 \pm 0.333$ after surgery) (Figure 5(1) and Table 5 (1)). Although the mineral-matrix ratio increased in all three patients after surgery in Group II ($2.266 \pm 0.172$ vs. $2.646 \pm 0.288$) (Figure 5(1)), the change in this parameter was not significant (Table 5 (2)). Mineral maturity, defined by the bone’s carbonate content and shown as $\text{CO}_3^{2-}/\text{ν1/PO}_4^{3-}/\text{ν1}$, did not change following PTX surgery in Group I ($n = 6$; $0.222 \pm 0.019$ before PTX and $0.232 \pm 0.027$ after surgery) (Figure 5(2), Table 5 (1)). Although mineral maturity decreased from $0.259$ to $0.196$ and $0.254$ to $0.209$ in two of three patients in Group III, the difference was not significant ($0.255 \pm 0.019$ vs. $0.222 \pm 0.034$) (Figure 5(2), Table 5 (2)). Crystallinity of the mineral is shown in Figure 5(3). Crystallinity did not change post-PTX surgery in either Group I or Group III (Figure 5(3), Tables 5 (1) and (2)). However, crystallinity is not expected to change within 3-4 weeks after PTX.

**Discussion**

Development of low turnover osteomalacia following PTX is generally observed in patients with renal hyperparathyroidism.$^{(7,19,29,34)}$ We previously demonstrated that mineralization around the osteocyte cell bodies and canaliculi was greater than that at the mineralization front after PTX followed by 2.0 μg/day of alfalcaldiol administration.$^{(7)}$ This finding is highly relevant and important as one of the causes of hypocalcemia and hypophosphatemia, namely, hungry bone syndrome after PTX in Group I.$^{(7)}$
Matrix mineralization by osteocytes may be disturbed by various factors, including Vit. D deficiency (11) and hypophosphatemia. (38) In this study of patients with renal hyperparathyroidism, hypomineralized matrix was found in large bone areas probably because of a severe mineralization deficiency (Figure 2 (left photo)). (10,11) Following PTX, the hypomineralized bone matrix around osteocytes was reduced within four weeks by administration of 2.0 μg/day of alfacalcidol administration. However, when the dose was reduced to 0.5 μg/day of alfacalcidol four weeks after PTX to avoid long-term consequences of low turnover bone disease with hypoparathyroidism, the area of hypomineralized bone increased by 6-fold over the course of the following year (Group II). When no alfacalcidol was administered after PTX (Group III), the area of hypomineralized bone doubled within 4 weeks following PTX. The higher dose of biologically active Vit. D clearly suppresses the function of parathyroid tissue, (12,13) but the lower dose of Vit. D or absence of Vit. D after PTX leads to increased hypomineralized bone area (Figures 4a, 4b and 4c). It is also possible that osteoid formation on the osteocyte lacunar walls continued after PTX, contributing to the increased hypomineralized bone matrix. The Vit. D receptor is expressed on osteocytes, (21) and biologically active Vit. D may stimulate the receptor on the osteocyte, leading to increased matrix mineralization.

These results indicate that Vit. D is required at least in moderate doses for adequate mineralization by osteocytes (Tables 3 and 4, Figures 2, 3 and 4). As a future study, whether the Vit. D sterols, including paricalcitol (19-nor-1α,25-dihydroxyvitamin D₂) (AbbVie Inc. North Chicago, Illinois, USA) activate mineralization by osteocytes or not should be investigated.
Raman spectroscopy was used to further characterize changes in the perilacunar matrix around osteocytes. Raman spectroscopy showed that, mineralized matrix did not change significantly in patients whether they received alfacalcidol or not after PTX. Crystallinity of the deposited mineral did not change either, but this was an expected result only 3-4 weeks after PTX. This analysis showed that, mineralized matrix did not change significantly in patients whether they received alfacalcidol or not after PTX. Crystallinity of the deposited mineral did not change either, but this was an expected result only 3-4 weeks after PTX.

The biopsies used here were embedded in plastic prior to Raman imaging. When sanding and polishing a surface for Raman, the plastic surface is flattened which then exposes some of the bone’s surface. In practice, patches of bone were exposed on a given surface, and even a small amount of surface plastic overlaying a section of bone will distort the Raman spectrum. In addition, given that the bone was embedded, bone near any surface, including near any osteocyte lacunae, would be plasticized which can alter this type of characterization.

The second limitation of the study is that the post-year one bone biopsy was performed only in patients of group II. The additional limitation of the analysis is that the subsample was small, and we could not get permission for all of the patients in the study to perform this analysis.

Based on these results, we suggest that that PTX followed by 2.0 μg/day of alfacalcidol administration is an important option to increase BMD in HD patients with hyperparathyroid bone disease caused by renal hyperparathyroidism. Biologically active Vit. D may be required at least in moderate doses for adequate mineralization by osteocytes to reduce hypomineralized bone area. However, a larger study is needed to
demonstrate this conclusively. Further study of osteocyte specific histological parameters and perilacunar changes in response to PTX and Vit. D administration in patients with renal hyperparathyroidism could further elucidate the role that osteocytes play in regulating bone matrix mineralization.

Acknowledgments

We would like to express our appreciation for the understanding of Towa Hospital Director, Dr. Tsunamasa Inou.

Authors’ roles;
Study design-AY, DBB, KN
Management of the patients-AY, TN.
PTX-AY, YT.
Bone biopsy-AY, TN.
Study conducted-AY, KT, DBB, JMW, JDD, MI, YT, TN, KN.
Data collection-AY, KT, DBB, JMW, JDD, MI, YT, TN, TT, AI, KN.
Bone histomorphometry-AY, AI.
The interpretation of the bone histomorphometric parameters-AY, DBB, JMW, JDD, MI, TT, AI.
Raman spectroscopy-JMW, JDD.
Management and analyses of all data-AY, KT, DBB, MI, TT, HO, KN.
Proofreading of the manuscript-AY, KT, DBB, JMW, JDD, MI, YT, SS, TN, TT, HO, AI, KN.
Approving of the manuscript-All authors
AY and DBB take responsibility for the integrity of the data analyses.
References


Table 1. Characteristics of HD patients in this study.

<table>
<thead>
<tr>
<th></th>
<th>Total (n = 19)</th>
<th>Group I (n = 15)</th>
<th>Group II (n = 4)</th>
<th>Group III (n = 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>58.4 ± 8.8 (39-71)</td>
<td>57.1 ± 9.3 (39-71)</td>
<td>52.8 ± 5.9 (45-59)</td>
<td>63.3 ± 5.2 (56-67)</td>
</tr>
<tr>
<td>Duration of HD (years)</td>
<td>14.1 ± 7.3 (1-25)</td>
<td>12.9 ± 7.5 (1-25)</td>
<td>12.0 ± 8.8 (2-23)</td>
<td>18.5 ± 4.7 (15-25)</td>
</tr>
<tr>
<td>Kidney disease (n)</td>
<td>12; 1; 1; 5</td>
<td>11; 1; 1; 2</td>
<td>2; 0; 0; 2</td>
<td>1; 0; 0; 3</td>
</tr>
<tr>
<td>Female : Male (n)</td>
<td>6 : 13</td>
<td>6 : 9</td>
<td>1 : 3</td>
<td>0 : 4</td>
</tr>
<tr>
<td>Bone biopsies</td>
<td>Pre-PTX</td>
<td>Pre-PTX</td>
<td>Pre-PTX</td>
<td>Post-PTX (3.8 ± 0.4 weeks)</td>
</tr>
</tbody>
</table>

Nineteen HD patients were divided into the three groups, including Group I, II and III.
HD; hemodialysis,
Kidney disease (chronic glomerular nephritis, polycystic kidney disease, hypertension, unknown)
PTX; total parathyroidectomy
All variables are expressed as mean ± SD (n = 19).
Table 2 (1). Bone metabolism parameters measured before and 3.8 ± 0.4 (3 or 4) weeks after PTX in Group I (n = 15).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Pre-PTX</th>
<th>Post-PTX (3 or 4 weeks)</th>
<th>p value</th>
<th>Power (%)</th>
<th>Normal values</th>
</tr>
</thead>
<tbody>
<tr>
<td>intact PTH (pg/mL)</td>
<td>12.10 ± 461.2</td>
<td>18.1 ± 21.3</td>
<td>&lt; 0.001</td>
<td>100</td>
<td>5.5-17.2</td>
</tr>
<tr>
<td>TRACP (U/L)</td>
<td>23.4 ± 8.6</td>
<td>7.3 ± 3.0</td>
<td>&lt; 0.001</td>
<td>100</td>
<td>90.9</td>
</tr>
<tr>
<td>DPDP (pmol/mL)</td>
<td>57.7 ± 65.7</td>
<td>9.3 ± 4.1</td>
<td>&lt; 0.001</td>
<td>90.9</td>
<td>30-182</td>
</tr>
<tr>
<td>PICP (ng/mL)</td>
<td>380.3 ± 457.0</td>
<td>475.3 ± 367.4</td>
<td>0.039</td>
<td>54.1</td>
<td>8.4-10.4</td>
</tr>
<tr>
<td>total ALP (U/L)</td>
<td>766.3 ± 576.8</td>
<td>950.5 ± 518.5</td>
<td>0.004</td>
<td>86.4</td>
<td>85-255</td>
</tr>
<tr>
<td>Ca (mg/dL)</td>
<td>9.9 ± 0.8</td>
<td>10.4 ± 1.8</td>
<td>N.S.</td>
<td>32.4</td>
<td>2.5-4.5</td>
</tr>
<tr>
<td>P (mg/dL)</td>
<td>5.5 ± 1.3</td>
<td>3.0 ± 1.6</td>
<td>0.002</td>
<td>96.5</td>
<td>10-65</td>
</tr>
</tbody>
</table>

Table 2 (2). Bone metabolism parameters measured 4 weeks and one year after PTX in Group II (n = 4).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Post-PTX (4 weeks)</th>
<th>Post-PTX (1 year)</th>
<th>p value</th>
<th>Power (%)</th>
<th>Normal values</th>
</tr>
</thead>
<tbody>
<tr>
<td>intact PTH (pg/mL)</td>
<td>6.8 ± 3.5</td>
<td>20.5 ± 15.0</td>
<td>N.S.</td>
<td>32.9</td>
<td>10-65</td>
</tr>
<tr>
<td>Ca (mg/dL)</td>
<td>12.3 ± 1.5</td>
<td>8.8 ± 0.5</td>
<td>N.S.</td>
<td>10</td>
<td>8.4-10.4</td>
</tr>
<tr>
<td>P (mg/dL)</td>
<td>2.3 ± 1.2</td>
<td>4.2 ± 1.7</td>
<td>N.S.</td>
<td>46.1</td>
<td>2.5-4.5</td>
</tr>
</tbody>
</table>

Table 2 (3). Bone metabolism parameters measured before and 4 weeks after PTX in Group III (n = 4).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Pre-PTX</th>
<th>Post-PTX (4 weeks)</th>
<th>p value</th>
<th>Power (%)</th>
<th>Normal values</th>
</tr>
</thead>
<tbody>
<tr>
<td>intact PTH (pg/mL)</td>
<td>961.5 ± 288.2</td>
<td>24.5 ± 15.7</td>
<td>0.125</td>
<td>98.5</td>
<td>10-65</td>
</tr>
<tr>
<td>TRACP (U/L)</td>
<td>24.2 ± 9.2</td>
<td>9.9 ± 1.9</td>
<td>0.125</td>
<td>66.8</td>
<td>5.5-17.2</td>
</tr>
<tr>
<td>DPDP (pmol/mL)</td>
<td>26.8 ± 7.1</td>
<td>6.3 ± 1.4</td>
<td>0.125</td>
<td>73</td>
<td>unknown</td>
</tr>
<tr>
<td>PICP (ng/mL)</td>
<td>300.3 ± 69.8</td>
<td>378.0 ± 104.0</td>
<td>0.125</td>
<td>30.2</td>
<td>30-182</td>
</tr>
<tr>
<td>total ALP (U/L)</td>
<td>394.8 ± 106.6</td>
<td>461.8 ± 123.4</td>
<td>0.375</td>
<td>10.2</td>
<td>85-255</td>
</tr>
<tr>
<td>Ca (mg/dL)</td>
<td>9.9 ± 0.4</td>
<td>9.6 ± 1.1</td>
<td>N.S.</td>
<td>8.4</td>
<td>8.4-10.4</td>
</tr>
<tr>
<td>P (mg/dL)</td>
<td>5.7 ± 0.8</td>
<td>2.8 ± 0.6</td>
<td>0.125</td>
<td>98.6</td>
<td>2.5-4.5</td>
</tr>
<tr>
<td>1,25 (OH)₂D₃ (pg/mL)</td>
<td>(-)</td>
<td>5.3 ± 2.2</td>
<td>(-)</td>
<td>(-)</td>
<td>20-60</td>
</tr>
</tbody>
</table>

PTX: total parathyroidectomy, HD: hemodialysis, CGN: chronic glomerular nephritis,
PCK: polycystic kidney disease, HT: hypertension
intact PTH: intact parathyroid hormone (An immunoradiometric assay (Allegro intact PTH, Nichols Institute Diagnostics, San Juan Capistrano, CA, USA) or an electrochemiluminescence immunoassay (Elecys PTH, Roche Diagnostics, GmbH, Mannheim, Germany), TRACP; tartrate resistant acid phosphatase (Means of colorimetry using 5-nitrophenyl phosphate as the substrate), DPDP; deoxypyridinoline (High-performance liquid chromatography), PICP; carboxy-terminal propeptide of human type I procollagen (Radioimmunoassay kit (PICP ORION; Orion Diagnostica, Espoo, Finland)), total ALP; total alkaline phosphatase (Means of colorimetry using 5-nitrophenyl phosphate as the substrate), Ca; calcium, P; phosphorus; Plasma 1,25 (OH)₂D₃ levels were measured 1 week after PTX in Group III.
Table 3 (1). Histomorphometric parameters on bone turnover and hypomineralized bone area before and 3.8 ± 0.4 (3 or 4) weeks after PTX in Group I (n = 15).

<table>
<thead>
<tr>
<th></th>
<th>Pre-PTX</th>
<th>Post-PTX (3 or 4 weeks)</th>
<th>p value</th>
<th>Power (%)</th>
<th>Normal values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oc.S/BS (%)</td>
<td>4.7 ± 3.7</td>
<td>0.2 ± 0.5</td>
<td>&lt;0.001</td>
<td>99.2</td>
<td>0.7 ± 0.7 (0-2.0)</td>
</tr>
<tr>
<td>ES/BS (%)</td>
<td>26.8 ± 12.0</td>
<td>3.2 ± 2.8</td>
<td>&lt;0.001</td>
<td>100</td>
<td>4.0 ± 2.0 (1.75-7.00)</td>
</tr>
<tr>
<td>Ob.S/BS (%)</td>
<td>23.6 ± 11.7</td>
<td>17.9 ± 21.4</td>
<td>0.083</td>
<td>44.2</td>
<td>4.4 ± 3.2 (0-9.5)</td>
</tr>
<tr>
<td>OS/BS (%)</td>
<td>49.2 ± 17.1</td>
<td>78.8 ± 25.3</td>
<td>0.003</td>
<td>95.5</td>
<td>14.3 ± 6.3 (7.0-25.0)</td>
</tr>
<tr>
<td>BFR/BS (mm²/mm²/year)</td>
<td>(+)</td>
<td>0.020 ± 0.015</td>
<td>(+)</td>
<td>(+)</td>
<td>0.014 ± 0.008 (0.001-0.016)</td>
</tr>
<tr>
<td>HM.B.Ar/B.Ar (%)</td>
<td>17.3 ± 12.8</td>
<td>2.6 ± 3.2</td>
<td>&lt;0.001</td>
<td>99.6</td>
<td>(-)</td>
</tr>
</tbody>
</table>

Table 3 (2). Histomorphometric parameters on bone turnover and hypomineralized bone area before and 4 weeks and one year after PTX in Group II (n = 4).

<table>
<thead>
<tr>
<th></th>
<th>Post-PTX (4 weeks)</th>
<th>Post-PTX (1 year)</th>
<th>p value</th>
<th>Power (%)</th>
<th>Normal values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oc.S/BS (%)</td>
<td>0.1 ± 0.1</td>
<td>0.1 ± 0.1</td>
<td>0.182</td>
<td>28.9</td>
<td>0.7 ± 0.7 (0-2.0)</td>
</tr>
<tr>
<td>ES/BS (%)</td>
<td>7.7 ± 6.1</td>
<td>7.7 ± 6.1</td>
<td>0.25</td>
<td>75.5</td>
<td>4.0 ± 2.0 (1.75-7.00)</td>
</tr>
<tr>
<td>Ob.S/BS (%)</td>
<td>3.1 ± 2.4</td>
<td>0 ± 0.1</td>
<td>0.25</td>
<td>42.9</td>
<td>4.4 ± 3.2 (0-9.5)</td>
</tr>
<tr>
<td>OS/BS (%)</td>
<td>58.3 ± 31.9</td>
<td>58.3 ± 31.9</td>
<td>0.625</td>
<td>11.1</td>
<td>14.3 ± 6.3 (7.0-25.0)</td>
</tr>
<tr>
<td>HM.B.Ar/B.Ar (%)</td>
<td>14.4 ± 5.0</td>
<td>14.4 ± 5.0</td>
<td>0.125</td>
<td>84.8</td>
<td>(-)</td>
</tr>
</tbody>
</table>

Table 3 (3). Histomorphometric parameters on bone turnover and hypomineralized bone area before and 4 weeks after PTX in Group III (n = 4).

<table>
<thead>
<tr>
<th></th>
<th>Pre-PTX</th>
<th>Post-PTX (4 weeks)</th>
<th>p value</th>
<th>Power (%)</th>
<th>Normal values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oc.S/BS (%)</td>
<td>7.4 ± 3.4</td>
<td>0.2 ± 0.3</td>
<td>0.125</td>
<td>75.5</td>
<td>0.7 ± 0.7 (0-2.0)</td>
</tr>
<tr>
<td>ES/BS (%)</td>
<td>30.2 ± 9.8</td>
<td>2.2 ± 3.9</td>
<td>0.125</td>
<td>84.5</td>
<td>4.0 ± 2.0 (1.75-7.00)</td>
</tr>
<tr>
<td>Ob.S/BS (%)</td>
<td>31.9 ± 8.2</td>
<td>26.9 ± 11.7</td>
<td>0.625</td>
<td>9.2</td>
<td>4.4 ± 3.2 (0-9.5)</td>
</tr>
<tr>
<td>OS/BS (%)</td>
<td>54.1 ± 10.1</td>
<td>81.9 ± 18.0</td>
<td>0.125</td>
<td>56.1</td>
<td>14.3 ± 6.3 (7.0-25.0)</td>
</tr>
<tr>
<td>BFR/BS (mm²/mm²/year)</td>
<td>(+)</td>
<td>0.026 ± 0.033</td>
<td>(+)</td>
<td>(+)</td>
<td>0.014 ± 0.006 (0.001-0.016)</td>
</tr>
<tr>
<td>HM.B.Ar/B.Ar (%)</td>
<td>6.0 ± 4.0</td>
<td>14.3 ± 3.5</td>
<td>0.125</td>
<td>49.5</td>
<td>(-)</td>
</tr>
</tbody>
</table>

PTX: total parathyroidectomy,
Oc.S/BS: osteoclast surface, ES/BS: eroded surface,
Ob.S/BS: osteoblast surface, OS/BS: osteoid surface, BFR/BS: bone formation rate normalized to bone surface,
HM.B.Ar/B.Ar: hypomineralized bone area
Normal values were referenced from the paper.\(^{(36)}\)
Table 4. Relationship between histomorphometric parameters of bone turnover and hypomineralized bone area obtained after PTX in Group I (n = 15) and those obtained after PTX in Group III (n = 4).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Group I</th>
<th>Group III</th>
<th>p value</th>
<th>Power (%)</th>
<th>Normal values</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oc.S/BS (%)</td>
<td>0.2 ± 0.5</td>
<td>0.2 ± 0.3</td>
<td>0.393</td>
<td>(-)</td>
<td>0.7 ± 0.7 (0-2.0)</td>
</tr>
<tr>
<td>ES/BS (%)</td>
<td>3.2 ± 2.8</td>
<td>2.2 ± 3.9</td>
<td>0.21</td>
<td>95.4</td>
<td>4.0 ± 2.0 (1.75-7.00)</td>
</tr>
<tr>
<td>Ob.S/BS (%)</td>
<td>17.9 ± 21.4</td>
<td>26.9 ± 11.7</td>
<td>0.024</td>
<td>8.5</td>
<td>4.4 ± 3.2 (0-9.5)</td>
</tr>
<tr>
<td>OS/BS (%)</td>
<td>78.8 ± 25.3</td>
<td>81.9 ± 18.0</td>
<td>1</td>
<td>5.3</td>
<td>14.3 ± 6.3 (7.0-25.0)</td>
</tr>
<tr>
<td>BFR/BS (mm²/mm²/year)</td>
<td>0.020 ± 0.015</td>
<td>0.026 ± 0.033</td>
<td>0.952</td>
<td>5.6</td>
<td>0.014 ± 0.008 (0.001-0.016)</td>
</tr>
<tr>
<td>HM.B.Ar/B.Ar (%)</td>
<td>2.6 ± 3.2</td>
<td>14.3 ± 3.5</td>
<td>0.004</td>
<td>98.9</td>
<td>(-)</td>
</tr>
</tbody>
</table>

PTX: total parathyroidectomy;
Oc.S/BS: osteoclast surface, ES/BS: eroded surface,
Ob.S/BS: osteoblast surface, OS/BS: osteoid surface, BFR/BS: bone formation rate normalized to bone surface,
HM.B.Ar/B.Ar: hypomineralized bone area

Normal values were referenced from the paper.36
Table 5 (1). Relationship between parameters on Raman spectroscopy obtained before and after PTX in Group I (n = 6).

<table>
<thead>
<tr>
<th></th>
<th>Pre-PTX</th>
<th>Post-PTX</th>
<th>p value</th>
<th>Power (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>v1-PO₄²⁻/Amide</td>
<td>2.317 ± 0.346</td>
<td>2.346 ± 0.333</td>
<td>N.S.</td>
<td>6</td>
</tr>
<tr>
<td>v1-PO₄²⁻/v1-CO₃²⁻</td>
<td>0.222 ± 0.019</td>
<td>0.232 ± 0.027</td>
<td>N.S.</td>
<td>17.1</td>
</tr>
<tr>
<td>Crystallinity/Maturity</td>
<td>0.063 ± 0.002</td>
<td>0.062 ± 0.002</td>
<td>N.S.</td>
<td>50.7</td>
</tr>
</tbody>
</table>

PTX: total parathyroidectomy, v1-PO₄²⁻/Amide: mineral matrix ratio, v1-PO₄²⁻/v1-CO₃²⁻: Type B carbonate substitution

Table 5 (2). Relationship between parameters on Raman spectroscopy obtained before and after PTX in Group III (n = 3).

<table>
<thead>
<tr>
<th></th>
<th>Pre-PTX</th>
<th>Post-PTX</th>
<th>p value</th>
<th>Power (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>v1-PO₄²⁻/Amide</td>
<td>2.666 ± 0.172</td>
<td>2.646 ± 0.288</td>
<td>N.S.</td>
<td>25</td>
</tr>
<tr>
<td>v1-PO₄²⁻/v1-CO₃²⁻</td>
<td>0.255 ± 0.019</td>
<td>0.222 ± 0.034</td>
<td>N.S.</td>
<td>16.6</td>
</tr>
<tr>
<td>Crystallinity/Maturity</td>
<td>0.062 ± 0.001</td>
<td>0.061 ± 0.002</td>
<td>N.S.</td>
<td>8.4</td>
</tr>
</tbody>
</table>

PTX: total parathyroidectomy, v1-PO₄²⁻/Amide: mineral matrix ratio, v1-PO₄²⁻/v1-CO₃²⁻: Type B carbonate substitution
Figure legends;

Figure 1- Osteoclasts, osteoblasts and osteocytes in patients with renal hyperparathyroidism
The relationships between osteocytes and both osteoclasts and osteoblasts in patients with renal hyperparathyroidism is shown.

Figure 2- Hypomineralized bone area before and after PTX in Group I
Hypomineralized bone area was observed in a HD patient suffering from renal hyperparathyroidism (left photo). Reduction of hypomineralized bone area was observed 4 weeks after total parathyroidectomy (PTX) with immediate autotransplantation of the diffuse hyperplastic parathyroid tissue followed by 2.0 μg/day of alfacalcidol administration in a Group I patient. Mineralization within bone matrix presumably mediated by the osteocytic perilacunar/canalicular system was observed 4 weeks after PTX. Mineralization within the matrix was activated by alfacalcidol administration (central photo). The single labelings caused by osteoblasts were also shown (central photo). Thereafter, hypomineralized bone area was increased again one year after PTX after reduction of alfacalcidol from 2.0 to 0.5 μg/day (right photo) (Group II). The lower dose of alfacalcidol is insufficient to maintain normal mineralization by osteocytes.

Figure 3a- Osteocyte canaliculi after PTX in Group I (upper panels)
The osteocyte canaliculi stained by tetracycline hydrochloride were clearly visible in a Group I patient after PTX followed by 2.0 μg/day of alfacalcidol administration. It is likely that mineralization within bone matrix presumably mediated by the osteocytic perilacunar/canalicular system was maintained if the HD patients receive 2.0 μg/day of
alfacalcidol after PTX. White arrows are pointing to osteocyte canaliculi stained by tetracycline hydrochloride.

**Figure 3b- Osteocyte canaliculi after PTX in Group I (lower panels)**

Osteocyte lacunae are shown and those on the right are stained by tetracycline hydrochloride. White arrows are pointing to osteocyte lacunar walls stained by tetracycline hydrochloride.

**Figure 4a- Hypomineralized bone area before and after PTX in Group III (upper panels)**

Increased hypomineralized bone area 4 weeks after PTX was found in a Group III patient not receiving alfacalcidol administration. The schema on the right shows both the single labelings caused by osteoblasts and hypomineralized bone area caused by osteocytes. These results indicate that vitamin D is required at least in moderate doses for adequate mineralization by osteocytes and osteoblasts. Mineralization in the osteocytic periacinar/canalicular system was not observed around the osteocyte lacunae in a patient not receiving alfacalcidol. White arrows are pointing to (1) mineralized matrix by osteoblasts and (2) hypomineralized matrix caused by lack of mineralization by osteocytes.

**Figures 4b and 4c- Higher resolution images of osteocyte lacunae (middle panels (4b) and lower panels (4c))**

Higher resolution images of osteocyte lacunae within the hypomineralized bone area, as well as osteoblasts on top of the surface of the respective area were shown. White arrows are pointing to hypomineralized matrix area.

**Figure 5(1)- PO₄³⁻-ν1/Amide I values before and after PTX in Groups I and III**
Mineral-matrix ratio is evaluated and shown as $\text{PO}_4^{3-} \text{-Amide I}$. The mineral-matrix ratio did not change following PTX surgery in Group I. However, although the mineral-matrix ratio increased in all three patients after surgery in Group III, the change in this parameter was not significant probably due to the limitation of statistical power in this group (Tables 5 (1) and (2)).

**Figure 5(2)- CO$_3^{2-}$-v1/PO$_4^{3-}$-v1 values before and after PTX in Groups I and III**

The maturity of mineral deposited to matrix, defined by its carbonate content, was evaluated and is presented as $\text{CO}_3^{2-}$-v1/$\text{PO}_4^{3-}$-v1 (Figure 5(2)). Mineral maturity did not change following PTX surgery in Group I. Although mineral maturity decreased from 0.259 to 0.196 and 0.254 to 0.209 in two patients of three patients after PTX in Group III, the difference was not significant.

**Figure 5(3)- Crystallinity/maturity values before and after PTX in Groups I and III**

Crystallinity did not change after PTX in either Group I or Group III. However, crystallinity is not expected to change within 3-4 weeks after PTX.